Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001635

Diclofenac for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Diclofenac sodium salt, 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid sodium salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H10Cl2NNaO2
Numéro CAS:
15307-79-6
Poids moléculaire :
318.13
Numéro MDL:
MFCD00082251
Code UNSPSC :
41116107
ID de substance PubChem :
329831520
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

diclofenac

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

[Na+].[O-]C(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl

InChI

1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1

Clé InChI

KPHWPUGNDIVLNH-UHFFFAOYSA-M

Informations sur le gène

human ... PTGS1(5742) , PTGS2(5743)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Diclofenac for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Standard NSAID and cyclooxygenase (COX) inhibitor. Major metabolites are 4´-hydroxydiclofenac and 5´-hydroxydiclofenac. Has been used as substrate selective for CYP2C9.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1144

Diclofenac sodium salt, Pharmaceutical Secondary Standard; Certified Reference Material

1188811

Diclofenac related compound A, United States Pharmacopeia (USP) Reference Standard

1188800

Diclofenac sodium, United States Pharmacopeia (USP) Reference Standard

D1039990

Diclofenac potassium, European Pharmacopoeia (EP) Reference Standard

S0765000

Diclofenac sodium, European Pharmacopoeia (EP) Reference Standard

18477

N-(2,6-Dichlorophenyl)-2-indolinone, analytical standard

1188709

Diclofenac potassium, United States Pharmacopeia (USP) Reference Standard

BP619

Diclofenac sodium, British Pharmacopoeia (BP) Reference Standard

BP828

N-(2,6-Dichlorophenyl)-2-indolinone, British Pharmacopoeia (BP) Reference Standard

BP598

Diclofenac diethylamine, British Pharmacopoeia (BP) Reference Standard

PHR2443

Diclofenac Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2446

Diclofenac Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2447

Diclofenac Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2445

Diclofenac Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2444

Diclofenac Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2442

Diclofenac Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2441

Diclofenac potassium, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Skull and crossbonesHealth hazardEnvironment
GHS06,GHS08,GHS09

Mention d'avertissement

Danger

Mentions de danger

H301,H361d,H372,H411

Classification des risques

Acute Tox. 3 Oral - Aquatic Chronic 2 - Repr. 2 - STOT RE 1

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

R N Brogden et al.
Drugs, 20(1), 24-48 (1980-07-01)
Diclofenac sodium, a phenylacetic acid derivative, is a non-steroidal, anti-inflammatory, analgesic agent advocated for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and allied conditions, and in the treatment of pain resulting from minor surgery, trauma and dysmenorrhoea. Published
George M Martin et al.
Journal of drugs in dermatology : JDD, 11(5), 600-608 (2012-04-25)
Diclofenac sodium 3% gel (Solaraze®) gained US approval for the treatment of actinic keratosis (AK) more than 10 years ago. Since the publication of the pivotal phase 3 studies, numerous clinical studies have assessed use of this therapy in a
D Aygün et al.
Histology and histopathology, 27(4), 417-436 (2012-03-01)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the purpose of anti-inflammation, antipyretic, and analgesia. For this aim, they are used for the alleviation of pain, fever, and inflammation associated with rheumatoid arthritis, sports injuries, and temporary pain. However, treatment
P A Todd et al.
Drugs, 35(3), 244-285 (1988-03-01)
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) advocated for use in painful and inflammatory rheumatic and certain non-rheumatic conditions. It is available in a number of administration forms which can be given orally, rectally or intramuscularly. Conveniently, dosage adjustments are
Paul L McCormack et al.
Drugs, 68(1), 123-130 (2007-12-18)
*A new formulation of the nonselective NSAID diclofenac sodium suitable for intravenous bolus injection has been developed using hydroxypropyl beta-cyclodextrin as a solubility enhancer (HPbetaCD diclofenac). * HPbetaCD diclofenac intravenous bolus injection was shown to be bioequivalent to the existing
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique